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Abstract
Background: Interferon-gamma release assays (IGRA) are more specific than the tuberculin skin test (TST) for the
diagnosis of Mycobacterium tuberculosis infection. Data on sensitivity are controversial in HIV infection.
Methods: IGRA (T-SPOT.TB) was performed using lymphocytes stored within 6 months before culture-confirmed
tuberculosis was diagnosed in HIV-infected individuals in the Swiss HIV Cohort Study.
Results: 64 individuals (69% males, 45% of non-white ethnicity, median age 35 years (interquartile range [IQR] 31-
42), 28% with prior AIDS) were analysed. Median CD4 cell count was 223 cells/μl (IQR 103-339), HIV-RNA was 4.7
log10 copies/mL (IQR 4.3-5.2). T-SPOT.TB resulted positive in 25 patients (39%), negative in 18 (28%) and
indeterminate in 21 (33%), corresponding to a sensitivity of 39% (95% CI 27-51%) if all test results were considered,
and 58% (95% CI 43-74%) if indeterminate results were excluded. Sensitivity of IGRA was independent of CD4 cell
count (p = 0.698). Among 44 individuals with available TST, 22 (50%) had a positive TST. Agreement between TST
and IGRA was 57% (kappa = 0.14, p = 0.177), and in 34% (10/29) both tests were positive. Combining TST and
IGRA (at least one test positive) resulted in an improved sensitivity of 67% (95% CI 52-81%). In multivariate analysis,
older age was associated with negative results of TST and T-SPOT.TB (OR 3.07, 95% CI 1,22-7.74, p = 0.017, per 10
years older).
Conclusions: T-SPOT.TB and TST have similar sensitivity to detect latent TB in HIV-infected individuals. Combining
TST and IGRA may help clinicians to better select HIV-infected individuals with latent tuberculosis who qualify for
preventive treatment.
Background
Tuberculosis (TB) continues to be a global public health
epidemic with 2 million deaths yearly [1]. One third of
the world’s population is latently infected with Mycobac-
terium tuberculosis [2]. HIV-infected individuals are par-
ticularly susceptible to TB, both from new infection
with rapid progression to active disease and reactivation
of latent infection occurring in 20-30% of subjects with
a positive tuberculin skin test (TST) [3-5].
There is still no reliable test to detect latent TB. The
TST with purified protein derivative (PPD) by the Man-
toux method has a limited sensitivity especially in HIV-
infected individuals [6-8], even after the introduction of
combination antiretroviral therapy [9]. Limitations of
TST include reader variability, false-positive results due
to cross-reactivity with environmental mycobacteria and
previous Bacillus Calmette-Guérin (BCG) vaccination,
and false-negative results due to anergy in immunosup-
pressed individuals [7]. Recently, interferon-gamma
based assays (IGRA) to detect specific cellular immune
response to antigens expressed in M. tuberculosis
(ESAT-6: early secretory antigenic target 6, and CFP-10:
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culture filtrate protein 10), but absent in BCG and many
environmental mycobacteria, have been reported to
improve sensitivity and specificity for the diagnosis of
TB [10-12]. Regarding sensitivity, however, published
studies in this area are highly variable in respect to sam-
ple size, type of assay, interpretation criteria, study
population and TB endemic setting. Since IGRA rely on
immune response, their performance may be impaired
in HIV-infection [11,13-15].
IGRA are already part of clinical practice in several
countries with low prevalence of TB [16]. In Switzer-
land, 2 IGRA are currently commercially available: a
whole-blood (QuantiFERON-TB Gold In-Tube™, Cel-
lestis Ltd. Victoria, Australia) and an enzyme-linked
immunospot assay (T-SPOT.TB™, Oxford Immunotec
Ltd., Abingdon, UK) [17]. Previous studies suggested
that sensitivity of T-SPOT.TB is less impaired than
QuantiFERON in the setting of advanced immunosup-
pression and HIV-infection [10,18,19].
We aimed to evaluate the sensitivity of T-SPOT.TB in
comparison to TST to identify HIV-infected individuals
with latent TB, who therefore qualify for preventive
treatment. All included patients developed culture-con-
firmed TB within 6 months; from this we deduce that
they had latent TB when they were enrolled in the
Swiss HIV Cohort Study and they were sampled.
Methods
Study design
T-SPOT.TB was retrospectively performed using frozen
viable lymphocytes of HIV-infected individuals partici-
pating in the Swiss HIV Cohort Study (SHCS) that had
been stored within 6 months before culture-confirmed
TB occurred. Performance of T-SPOT.TB was compared
with TST, when available.
Study population
The SHCS [20] is a large prospective cohort study with
continuous enrolment of adult HIV-infected individuals.
Basic socio-demographic characteristics, data on the
clinical course (occurrence of opportunistic infections,
death), co-infection with hepatitis B and C, TST, antire-
troviral therapy, co-medication (prophylaxis and treat-
ment of opportunistic infections), immunologic and
virologic parameters are collected at enrolment into the
study and every 6 months thereafter on standardised
data collection forms. At registration and at every fol-
low-up visit, plasma samples are frozen for further ana-
lysis. In addition, once a year a sample of viable
peripheral blood mononuclear cells (PBMC) is stored
(three aliquots of at least 1.5 million cells). AIDS-defin-
ing diseases are recorded using the 1993 revised clinical
definition of AIDS from the Centers for Disease Control
and Prevention [21]. The cause of death is reported
using the 10th revision of the International Classification
of Diseases and Related Health Problems (ICD-10) [22].
Laboratory assay
T-SPOT.TB™ (Oxford Immunotec Ltd., Abingdon, UK)
is a simplified variant of the enzyme-linked immunospot
(ELISPOT) assay technique for the determination of
effector T-cells which secrete interferon gamma in
response to stimulation by antigens specific for M.
tuberculosis. T-SPOT.TB was performed by using a
commercial kit according to the manufacturer’s instruc-
tions [17]. Each patient test required 4 wells: one for the
negative control (containing no antigen), one for the
positive control (phytohaemagglutinin) and 2 for the M.
tuberculosis antigens, Panel A (ESAT-6) and B (CFP-10).
Evaluating the number of spots obtained provided a
measurement of the frequency of M. tuberculosis sensi-
tive cells. The test result was considered “positive” if the
number of spots per test well was ≥ 6 in either of both
Panel A and B. The test result was considered “negative”
if both Panel A and B showed < 6 spots. Where the
positive control was < 20 spots, or the negative control
≥ 10 spots, the test was scored as “indeterminate”. Of
note, interpretation criteria of T-SPOT.TB by Food and
Drug Administration (FDA) for the use of the test in
the USA differ from those used in other countries,
where an “indeterminate” test result occurs if the nega-
tive control is either > 10 spots, or ≤ 10 spots but the
positive control is < 20 spots and Panel A or B < 5
spots. According to USA guidelines, a borderline test
result occurs if Panel A or B is between 5 and 7 spots
and the negative control ≤ 10 spots [19].
Viability of stored frozen lymphocytes
We assumed that T-SPOT.TB was feasible using stored
frozen lymphocytes. According to Oxford Immunotec
Ltd., freezing of PBMC is possible, but the use of fresh
white blood cells is recommended because of the risk of
some deterioration in the performance of the assay
[Oxford Immunotec, Technical bulletins Nr 1, 4, 10,
2005].
Following steps were undertaken to guarantee the good
performance and the correct interpretation of the test
using frozen lymphocytes: a) Time between collection
and freezing of samples, and procedures of freezing and
storing PBMC were performed according to a specific
protocol of the SHCS, assuring comparable quality of
stored cells in all study centers. Viability of frozen PBMC
was checked regularly. b) After thawing, viable cells were
counted using the trypan blue dye exclusion method,
confirming that stored cells were still able to produce
interferon gamma. Recovery had to be more than 70% of
the original input. The procedures a) and b) were vali-
dated in several studies performed within the framework
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of the Swiss HIV Cohort Study [23-25]. c) For each
patient, a negative control (without antigen) and a posi-
tive control (proliferation assay) were performed, the last
one with addition of phytohaemagglutinin mitogens,
which induce the production of gamma interferon, con-
firming again the viability of the cells used for the IGRA.
The 2 wells containing M. tuberculosis specific antigens
(ESAT-6 and CFB-10) were only read if both negative
and positive controls had been performed and were valid
according to the manufacturer’s protocol.
Statistical analysis
Basic socio-demographic characteristics, CD4 cell count,
HIV viral load, and antiretroviral therapy were com-
pared using the Chi-square test or Fisher’s exact test for
categorical variables, and the Mann-Whitney or Krus-
kal-Wallis test for continuous variables. Logistic regres-
sion was used to assess factors associated with a positive
T-SPOT.TB result, and with negative results of both
T-SPOT.TB and TST. We built the final model using a
forward stepwise approach, adding each factor signifi-
cant at the level of 0.1 in the model one by one. Agree-
ment between T-SPOT.TB and TST was determined by
calculation of Cohen’s kappa coefficient.
All analyses were performed using STATA™ software
version 11 for Windows (STATA Corp, College Station,
Texas, USA).
Ethical approval
The SHCS was approved by the relevant ethics commit-
tees of the participating centres, and written consent
was obtained from all study participants.
Results
Study population
Among 242 HIV-infected individuals who developed
culture-confirmed TB between 1993 and 2005 after
enrolment in the SHCS, we identified 64 subjects with a
sample of viable lymphocytes collected prior to TB diag-
nosis that could be analyzed. Table 1 summarises the
baseline characteristics of participants. Most patients
(69%) were males, the median age was 35 years (inter-
quartile range [IQR] 31-42), 45% were of non-white eth-
nicity, and 18% had previously been diagnosed with an
AIDS defining condition. The median CD4 cell count
was 223 cells/μL (IQR 103-339), and the median HIV-
RNA was 4.7 copies/mL (IQR 4.3-5.2) at the time of
cells sampling prior to TB diagnosis. Culture-confirmed
Table 1 General characteristics of the study population (n = 64) according to results of T-SPOT.TB assay
Variable Positive T-SPOT.TB Negative
T-SPOT.TB
Indeterminate T-SPOT.TB p-value
N = 25 N = 18 N = 21
n % n % n %
Median age, IQR (years) 35 32-40 36 30-43 35 29-44 0.915
Males 18 72 12 67 14 67 0.904
Median body mass index, IQR (kg/m2) 22 20-25 22 21-25 23 20-26 0.906
White ethnicity 13 52 7 39 9 53 0.670
Prior AIDS-defining condition 5 20 5 25 8 38 0.396
Risk MSM 5 20 4 22 7 28 0.978
Heterosexual 13 52 10 56 4 22
Intravenous drug use 7 38 10 48 5 24
TB disease Pulmonary 13 52 7 39 13 62 0.357
Extrapulmonary 8 32 9 50 7 33
Pulmonary and extrapulmonary 4 16 2 11 1 5
Median CD4 cell count at TB diagnosis, IQR (cells/μL) 235 106-330 169 70-297 229 130-300 0.572
Median HIV-RNA at TB diagnosis, IQR (log10 copies/mL) 4.7 3.5-5.6 5.0 4.6-5.2 4.9 4.6-5.3 0.531
Median CD4 cell count at cells sampling, IQR (cells/μL) 235 122-320 147 70-349 256 108-379 0.498
Median CD8 cell count at cells sampling, IQR (cells/μL) 614 448-889 842 460-1191 835 510-1417 0.308
Median HIV-RNA at cells sampling, IQR (log10 copies/mL) 4.8 3.2-5.3 4.9 4.6-5.0 4.6 4.3-5.1 0.868
Antiretroviral therapy at cells sampling 13 52 14 78 12 57 0.211
Time between cells sampling and TB diagnosis, IQR (days) 63 15-126 57 12-163 72 20-284 0.786
Time between cells sampling and performance of IGRA, IQR (months) 81 48-135 107 70-141 123 84-167 0.142
TST ≥ 5 mm 10 40 7 39 5 24 0.414
< 5 mm 7 28 8 44 7 33
missing 8 32 3 17 9 43
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TB was diagnosed after a median of 680 days (IQR 208-
1948) after enrolment in the SHCS.
T-SPOT.TB
The IGRA assay was performed using lymphocytes
obtained at a median of 91 days (IQR 47-167) before
active tuberculosis was diagnosed. T-SPOT.TB assay
resulted positive in 25 patients (39%), negative in 18
(28%) and indeterminate in 21 (33%), corresponding to
a sensitivity of 39% (95% confidence interval [CI] 27-
51%) if all test results were considered, and 58% (95%
CI 43-74%) if indeterminate results were excluded.
Among 21 indeterminate test results, 9 (43%) had a
positive nil control and 12 (57%) a fair mitogen control,
i.e. there were less than 20 positive spots.
Overall, there was no significant correlation between
results of T-SPOT.TB and the degree of immunosup-
pression as measured by the CD4 cell count (Spearman
correlation coefficient r = 0.02) (Figure 1). However, in
patients with a positive T-SPOT.TB result we observed
an association between higher number of spots and
increasing CD4 cell count (p = 0.037), but not with
CD8 cell count (p = 0.244), suggesting improved sensi-
tivity of T-SPOT.TB in subjects with less advanced
immunosuppression. In both univariate and multivariate
analyses, regardless whether indeterminate results were
excluded from the analysis, sensitivity of T-SPOT.TB
was independent of age, sex, body mass index, ethnicity,
HIV viral load, HIV clinical stage, antiretroviral treat-
ment, and time between freezing of cells samples and
performance of IGRA (Table 2).
The probability of scoring an indeterminate T-SPOT.TB
result in our study was not related to the degree of immu-
nosuppression, antiretroviral treatment or time between
lymphocytes sampling and performance of IGRA.
Tuberculin skin test
Among 44 individuals with available TST results, 22 had
a positive TST, defined as a skin induration of ≥ 5 mm,
corresponding to a sensitivity of 50% (95% CI 35-65%).
The median time between performance of TST and
diagnosis of active TB was 379 days (IQR 70-1267).
In contrast to T-SPOT.TB, sensitivity of TST was
clearly dependent on age and CD4 cell count, being
lower in older patients and in those with more advanced
immunosuppression (Figure 2). In multivariate analysis,
after adjustment for age, gender, ethnicity, HIV clinical
stage, CD4 cell count and antiretroviral therapy, a posi-
tive TST test result was associated with age (OR 0.17,
95% CI 0.05-0.63, p = 0.008, per 10 years older) and
CD4 cell count (OR 5.11, 95% CI 1.04-26.4, p = 0.022
for CD4 cell count above 100 cells/μl).
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Table 2 Factors associated with a positive T-SPOT.TB in 43 patients with determinate test results. Univariate and
multivariate analysis
Variable Univariate analysis Multivariate analysis
OR 95% CI p-value Adjusted OR 95% CI p-value
Age, per 10 years older 1.02 0.52-2.03 0.945 1.23 0.53-2.87 0.624
Female 0.78 0.21-2.89 0.707 1.36 0.17-11.1 0.775
Body mass index, per 5 kg/m2 increase 0.62 0.20-1.89 0.403 0.59 0.18-2.00 0.398
Non-white ethnicity 1.70 0.50-5.83 0.397 - - -
Risk Men who have sex with men 1* - - - - -
Heterosexual 1.04 0.22-4.91 0.960 - - -
Intravenous drug use 1.40 0.23-8.46 0.714 - - -
Prior AIDS-defining condition 0.65 0.16-2.70 0.553 - - -
Antiretroviral treatment 0.31 0.26-1.21 0.120 0.87 0.14-5.65 0.888
CD4 cell count, per 50 cells/μL increase 1.01 0.85-1.20 0.904 - - -
CD4 cell count ≥200 versus < 200 cells/μL 2.55 0.72-8.96 0.146 1.41 0.27-7.39 0.682
CD8 cell count, per 50 cells/μL increase 0.97 0.93-1.02 0.292 - - -
Positive TST (≥ 5 mm) 1.63 0.40-6.63 0.493 - - -
Extrapulmonary versus pulmonary TB 2.13 0.61-7.41 0.237 - - -
Time between cells freezing and IGRA performance, per month 0.99 0.98-1.01 0.453 - - -
* Reference category
Figure 2 Proportion of positive test results of TST and T-SPOT.TB and indeterminate T-SPOT.TB results according to CD4 cell count
(test for trend p = 0.135 for the association between CD4 cell count and T-SPOT.TB).
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Comparison between T-SPOT.TB and TST
Among 44 patients with available results of TST and T-
SPOT.TB, overall agreement between both tests was
noted in 57% of patients (kappa = 0.14, p = 0.177). In
29 subjects with positive test results by either TST or
T-SPOT.TB, only 10 (34%) had positive results with
both modalities.
Among 22 individuals with a positive TST, 10 (45%)
had also a positive T-SPOT.TB, 7 (32%) a negative and
5 (23%) an indeterminate IGRA result, whereas among
22 individuals with a negative TST, 7 (32%) had a posi-
tive T-SPOT.TB, 8 (36%) a negative, and 7 (32%) an
indeterminate IGRA result (p = 0.745). If both TST and
T-SPOT.TB results were combined (at least one test
positive) and indeterminate results excluded a sensitivity
of 67% (95% CI 52-81%) was reached.
In univariate and multivariate analyses (Table 3), older
age was the only risk factor of having negative test
results with both TST and T-SPOT.TB (OR 3.07, 95%
CI 1,22-7.74, p = 0.017, per 10 years older).
Discussion
This study evaluating an interferon-gamma release assay,
T-SPOT.TB, in 64 HIV-infected adults who all devel-
oped culture-confirmed TB after enrolment in the Swiss
HIV Cohort Study indicates that T-SPOT.TB has a simi-
lar sensitivity to TST to detect latent TB in HIV-
infected individuals. However, there was poor agreement
between T-SPOT.TB and TST results. In contrast to
TST, sensitivity of T-SPOT.TB was independent of the
level of immunodeficiency, although a trend towards
higher number of spot forming units with increasing
CD4 cell count was observed in patients with a positive
T-SPOT.TB. Importantly, combination of TST and T-
SPOT.TB with at least one test positive resulted in
improved sensitivity. This is likely to be useful in clinical
practice to better identify HIV-infected individuals with
latent TB who qualify for preventive treatment.
Sensitivity of T-SPOT.TB of 39-58% in our study was
lower than in published studies [10,11,23,26-28]. In the
absence of a gold standard to diagnose latent or culture
negative TB, assessments of accuracy of tests for TB are
difficult, especially in the context of immunodeficiency.
So far, sensitivity of IGRA for latent TB has been mainly
estimated by comparison with TST in cross-sectional stu-
dies, or by assessing the number of positive IGRA results
in patients with culture-confirmed TB. Because TST and
IGRA are indirect tests that measure immunologic
responses and do not detect the causative organism,
assessment of sensitivity among persons with positive
TST or active TB might not reliably estimate sensitivity
for latent TB. In our study, T-SPOT.TB was performed
in a highly selected population, namely HIV-infected
individuals shortly before they developed culture-con-
firmed TB, providing a reliable approximation of patients
with latent TB in an area of low TB transmission, since
reinfection with M. tuberculosis was unlikely. The quite
low sensitivity of T-SPOT.TB in our population was
independent of socio-demographic characteristics,
including ethnicity and country of origin, level of immu-
nodeficiency and antiretroviral treatment, suggesting that
immunologic differences implied in the progression of
latent infection to active disease might negatively affect
IGRA results. The suboptimal sensitivity of Interferon-
based in-vitro assays, especially in immunocompromised
individuals, emphasizes the need for alternative markers
for diagnosing tuberculosis, such as interferon-inducible
protein (IP-10), which appeared less influenced by HIV
infection. Further studies are needed to test the clinical
impact of these findings [15,29].
The major concern in using T-cell based assays in
the setting of HIV infection is the influence of
Table 3 Factors associated with negative test results of both T-SPOT.TB and TST
Variable Univariate analysis Multivariate analysis
OR 95% CI p-value Adjusted OR 95% CI p-value
Age, per 10 years older 2.93 1.24-6.91 0.014 3.07 1.22-7.74 0.017
Female 0.96 0.20-4.52 0.073 2.22 0.33-14.7 0.409
Body mass index, per 5 kg/m2 increase 1.71 0.62-4.69 0.300
Non-white ethnicity 0.22 0.04-1.55 0.092 - - -
Risk Men who have sex with men 1* - - - - -
Heterosexual 0.25 0.15-1.14 0.134 - - -
Intravenous drug use 0.67 0.13-3.45 0.629 - - -
Prior AIDS-defining condition 3.35 0.87-13.0 0.080 3.02 0.56-16.2 0.198
Antiretroviral treatment 1.24 0.31-4.96 0.764 0.71 0.13-4.01 0.699
CD4 cell count, per 50 cells/μL increase 0.86 0.70-1.04 0.123 - - -
CD4 cell count ≥200 versus < 200 cells/μL 0.41 0.11-1.46 0.168 0.46 0.10-2.05 0.306
CD8 cell count, per 50 cells/μL increase 1.01 0.96-1.05 0.740 - - -
Extrapulmonary versus pulmonary TB 1.22 0.34-4.32 0.759 - - -
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immunodeficiency on sensitivity. While some studies
suggested that IGRA were less influenced by HIV infec-
tion [15,18,26-28,30,31] other studies reported loss of
sensitivity with severe immunodeficiency, in particular
when CD4 cell counts were less than 100 cells/μl
[15,28,30,32-35]. We observed a clear association
between CD4 cell count and TST but not between CD4
cell count and T-SPOT.TB, although a trend towards
higher number of spot forming cells with increasing
CD4 cell count was noted in patients with positive T-
SPOT.TB result. As both tests rely on a T-cell mediated
immune response, this difference might also result from
the cut-off chosen for scoring a positive T-SPOT.TB. A
recent publication suggests that accuracy in HIV-
infected patients improves when the number of spot
forming cells from the T-SPOT.TB test is related to
CD4 count [36].
In line with prior studies [18,28,37-39], we observed
poor agreement between TST and T-SPOT.TB. However,
combination of TST and T-SPOT.TB with at least one
test positive was shown to enhance sensitivity to detect
latent TB in HIV co-infection. This is clinically relevant,
since easier and more accurate diagnosis of latent TB
implies start of preventive treatment, which was demon-
strated to be highly effective [9]. In multivariate analysis,
older age was the only risk factor of scoring both tests
negative, indicating a limitation of this strategy.
The high number of indeterminate test results in our
study was not associated with lower CD4 cell counts in
contrast to other reports [37,38,40]. As no correlation
between time of lymphocyte sampling and performance
of T-SPOT.TB was noted, it is also unlikely that the
quality of cell samples was impaired.
Limitations and strengths
We acknowledge some limitations. The use of frozen
stored lymphocytes to perform T-SPOT.TB might have
impaired the ability of producing gamma-interferon,
leading to an underestimation of sensitivity. However,
viability of cells was meticulously checked, validated in
several studies of the Swiss HIV Cohort Study [23-25],
and T-SPOT.TB was always performed together with
mitogens and nil controls, as described in the method
section. As TB negative subjects were not included in
our study, we could not estimate specificity of T-SPOT.
TB and TST. However, the focus of this study was on
sensitivity, because improvement of sensitivity is the
main diagnostic need in latent TB in HIV-infected indi-
viduals. Due to the retrospective character of this study,
results of TST were not available for all patients, and
information on previous BCG vaccination was not col-
lected in the SHCS database. Due to the small amount
of viable peripheral blood mononuclear cells routinely
stored in the Swiss HIV Cohort Study (3 aliquots of 1.5
million cells) we were not able to perform additional
analysis such as the measurement of T regulatory cells.
Moreover, we were not able to repeat T-SPOT.TB at
later time points before culture-confirmed active tuber-
culosis was diagnosed, because cells samples were col-
lected only once a year after enrolment in the Swiss
HIV Cohort Study according to the protocol.
Strengths of this study were the inclusion of HIV-
infected individuals with latent TB who all developed
culture-confirmed TB in a low endemic area, and eva-
luation of combined testing with TST to enhance sensi-
tivity of T-SPOT.TB. This is clinically relevant, since
easier and more accurate diagnosis of latent TB implies
start of preventive chemotherapy, that was shown to be
highly effective in HIV-infected individuals [9].
Conclusion
In conclusion, T-SPOT.TB and TST have similar sensi-
tivity to detect latent TB in HIV-infected individuals.
Combination of TST and T-SPOT.TB with at least one
test positive resulted in enhanced sensitivity. This is
likely to help clinicians in their decision to start treat-
ment of latent TB in HIV-infected individuals. Further
studies are needed to confirm our findings and to evalu-
ate newer biomarkers like IP-10 for the diagnosis of
tuberculosis in the setting of immunodeficiency and in
particular HIV infection.
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